POST GRADUATE DIPLOMA IN PHARMACEUTICAL SALES MANAGEMENT (PGDPSM)

Term-End Examination June, 2025

MVE-004: DRUG REGULATORY AFFAIRS

Time: 2 Hours Maximum Marks: 50

Note: Answer any five questions. All questions carry equal marks.

1. (a) Define the following:

 $1 \times 5 = 5$

- (i) Drug formulation
- (ii) Clinical trials
- (iii) Schedule Y
- (iv) Bulk drug
- (v) Gene technology

	(b)	Discuss the types of toxicity studies for
		pre-clinical evaluation of drugs. 5
2.	(a)	What are the approval and prohibitions
		of novel diagnostic agents in Govt.
		notifications? 5
	(b)	Explain the process of application for
		getting the permission to import new
		drugs. 5
3.	(a)	Who is a Drug Inspector ? How is a
		drug inspected? 5
	(b)	Write the salient features of
		adulterated drug. 5
4.	Wri	te short notes on the following:
		$2.5 \times 4 = 10$
	(a)	Task force of DBT
	(b)	Shelf life
	(c)	Poisons Act
	(d)	Expiry date of drug

B-1752/MVE-004

- 5. Differentiate between the following: 5+5
 - (a) Phase I and Phase II Clinical Trials
 - (b) Institutional Biosafety Committee and District Level Committee
- Describe Narcotic Drugs and Psychotropic
 Substances (NDPS) Act, 1985.
- 7. Write notes on any *two* of the following:

5+5

- (a) Dynamics of Indian Pharmaceutical Industry
- (b) Procedure for pricing of formulation
- (c) Factors affecting the potency of drug during storage
- (d) Drugs Enquiry Committee

 $\times \times \times \times \times$